HER-2 overexpression or amplification has been widely studied as a prognostic and predictive factor in early breast cancer patients but its role is still controversial (Trock et al, 2000; Ravdin, 2001; Sledge, 2001; Yamauchi et al, 2001; Goldhirsch et al, 2003). This evidence concerns the gene ERBB2 and breast carcinoma.